The Role of MicroRNAs in Prostate Cancer Progression

Overview

Journal Transl Androl Urol

Date 2016 Jan 28

PMID 26813625

Citations 17

Authors

U-Ging Lo

Diane Yang

Jer-Tsong Hsieh

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is the most common male malignancy and the second highest cause of cancer-related mortality in United States. MicroRNAs (miRNAs) are small non-coding RNAs that represent a new mechanism to regulate mRNA post-transcriptionally. It is involved in diverse physiological and pathophysiological process. Dysregulation of miRNAs has been associated with the multistep progression of PCa from prostatic intraepithelial neoplasia (PIN), localized adenocarcinoma to metastatic castration-resistance PCa (CRPC). Identification of unique miRNA could provide new biomarkers for PCa and develop into therapeutic strategies. In this review, we will summarize a broad spectrum of both tumor suppressive and oncogenic miRNAs, and their mechanisms contribute to prostate carcinogenesis.

Citing Articles

miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer.

Salgado-Hernandez S, Martinez-Retamoza L, Ocadiz-Delgado R, Perez-Mora S, Cedeno-Arboleda G, Gomez-Garcia M Cancers (Basel). 2025; 17(1.

PMID: 39796656 PMC: 11718816. DOI: 10.3390/cancers17010026.

Exosomal miR-664a-5p as a therapeutic target biomarker for PARP inhibitor response in prostate cancer.

Kim M, Moon H, Jo M, Lee J Am J Cancer Res. 2024; 14(8):3789-3799.

PMID: 39267686 PMC: 11387859. DOI: 10.62347/QYZS2620.

Key genes and molecular mechanisms related to Paclitaxel Resistance.

Alalawy A Cancer Cell Int. 2024; 24(1):244.

PMID: 39003454 PMC: 11245874. DOI: 10.1186/s12935-024-03415-0.

Role of MicroRNA-21 in Prostate Cancer Progression and Metastasis: Molecular Mechanisms to Therapeutic Targets.

Singh V, Rajak N, Singh Y, Singh A, Giri R, Garg N Ann Surg Oncol. 2024; 31(7):4795-4808.

PMID: 38758485 DOI: 10.1245/s10434-024-15453-z.

MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer.

Ghamlouche F, Yehya A, Zeid Y, Fakhereddine H, Fawaz J, Liu Y Transl Oncol. 2023; 28:101613.

PMID: 36608541 PMC: 9827391. DOI: 10.1016/j.tranon.2022.101613.

References

Chen Y, Zaman M, Deng G, Majid S, Saini S, Liu J . MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila). 2010; 4(1):76-86. PMC: 3894108. DOI: 10.1158/1940-6207.CAPR-10-0167. View

Li Y, Chan S, Brand L, Hwang T, Silverstein K, Dehm S . Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2012; 73(2):483-9. PMC: 3549016. DOI: 10.1158/0008-5472.CAN-12-3630. View

Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim H . miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells. 2009; 27(8):1712-21. PMC: 3400149. DOI: 10.1002/stem.101. View

Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez P, Iborra F . miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One. 2009; 4(10):e7542. PMC: 2763222. DOI: 10.1371/journal.pone.0007542. View

Li T, Li D, Sha J, Sun P, Huang Y . MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009; 383(3):280-5. DOI: 10.1016/j.bbrc.2009.03.077. View

Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M . Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008; 14(8):2334-40. DOI: 10.1158/1078-0432.CCR-07-4667. View

Voegel J, Heine M, Tini M, Vivat V, Chambon P, Gronemeyer H . The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 1998; 17(2):507-19. PMC: 1170401. DOI: 10.1093/emboj/17.2.507. View

Ahmed S, Nawshad A . Complexity in interpretation of embryonic epithelial-mesenchymal transition in response to transforming growth factor-beta signaling. Cells Tissues Organs. 2007; 185(1-3):131-45. PMC: 2043381. DOI: 10.1159/000101314. View

Wei J, Xu G, Wu M, Zhang Y, Li Q, Liu P . Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res. 2008; 28(1A):327-34. View

10.

Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl E, Nitsch R . A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol. 2008; 10(8):987-93. DOI: 10.1038/ncb1759. View

11.

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

12.

Dong Q, Meng P, Wang T, Qin W, Qin W, Wang F . MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One. 2010; 5(4):e10147. PMC: 2854685. DOI: 10.1371/journal.pone.0010147. View

13.

Mu P, Han Y, Betel D, Yao E, Squatrito M, Ogrodowski P . Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009; 23(24):2806-11. PMC: 2800095. DOI: 10.1101/gad.1872909. View

14.

Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K . Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011; 38(4):1093-101. DOI: 10.3892/ijo.2011.919. View

15.

Lee Y, Dutta A . The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007; 21(9):1025-30. PMC: 1855228. DOI: 10.1101/gad.1540407. View

16.

Dong J, Boyd J, Frierson Jr H . Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate. 2001; 49(3):166-71. DOI: 10.1002/pros.1131. View

17.

Leotoing L, Manin M, Monte D, Baron S, Communal Y, Lours C . Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation. J Mol Endocrinol. 2007; 39(2):151-62. DOI: 10.1677/JME-07-0021. View

18.

Ruizeveld de Winter J, Janssen P, Sleddens H, Trapman J, Brinkmann A, Santerse A . Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol. 1994; 144(4):735-46. PMC: 1887232. View

19.

Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M . miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009; 69(6):2287-95. DOI: 10.1158/0008-5472.CAN-08-2894. View

20.

Aalto A, Pasquinelli A . Small non-coding RNAs mount a silent revolution in gene expression. Curr Opin Cell Biol. 2012; 24(3):333-40. PMC: 3372702. DOI: 10.1016/j.ceb.2012.03.006. View